1
Clinical Trials associated with Recombinant tyrosinase-related protein-2 peptide vaccine(NCI)Immunization of HLA-0201 Positive Patients With Metastatic Melanoma Using a Peptide From Tyrosinase-related Protein 2 (TRP-2)
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may be an effective treatment for metastatic melanoma.
PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy plus interleukin-2 to that of vaccine therapy alone in treating patients who have metastatic melanoma that has not responded to previous treatment.
100 Clinical Results associated with Recombinant tyrosinase-related protein-2 peptide vaccine(NCI)
100 Translational Medicine associated with Recombinant tyrosinase-related protein-2 peptide vaccine(NCI)
100 Patents (Medical) associated with Recombinant tyrosinase-related protein-2 peptide vaccine(NCI)
100 Deals associated with Recombinant tyrosinase-related protein-2 peptide vaccine(NCI)